Semaglutide data were analyzed to assess effects of treatment as a function of CV risk predicted using the CV risk prediction model. A CV risk model was developed with independent data from the LEADER trial (liraglutide vs placebo), considering baseline variables common to all datasets. (SUSTAIN) and oral (PIONEER) semaglutide phase 3a clinical trial programs were combined according to randomized treatment (semaglutide or comparators) and analyzed to assess time to first MACE and its individual components. This post hoc analysis examined CV effects of semaglutide in subjects across a continuum of baseline CV risk. However, there is little evidence for an effect of semaglutide on MACE in subjects not at high risk of CV events. semaglutide and 0.79 for once-daily oral semaglutide). Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events (MACE defined as CV death, non-fatal stroke, non-fatal myocardial infarction) with semaglutide than with placebo (hazard ratio : 0.74 for once-weekly s.c. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
0 Comments
Leave a Reply. |